• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Biomol Struct Dyn. Elucidating biophysical basis of binding of inhibitors to SARS-CoV-2 main protease by using molecular dynamics simulations and f

tetano

Editor, Senior Moderator
J Biomol Struct Dyn. 2020 May 12:1-21. doi: 10.1080/07391102.2020.1768149. [Epub ahead of print]
Elucidating biophysical basis of binding of inhibitors to SARS-CoV-2 main protease by using molecular dynamics simulations and free energy calculations.


Sk MF[SUP]1[/SUP], Roy R[SUP]1[/SUP], Jonniya NA[SUP]1[/SUP], Poddar S[SUP]1[/SUP], Kar P[SUP]1[/SUP].

Author information




Abstract

The recent outbreak of novel "coronavirus disease 2019" (COVID-19) has spread rapidly worldwide, causing a global pandemic. In the present work, we have elucidated the mechanism of binding of two inhibitors, namely α-ketoamide and Z31792168, to SARS-CoV-2 main protease (M[SUP]pro[/SUP] or 3CL[SUP]pro[/SUP]) by using all-atom molecular dynamics simulations and free energy calculations. We calculated the total binding free energy (ΔG[SUB]bind[/SUB]) of both inhibitors and further decomposed ΔG[SUB]bind[/SUB] into various forces governing the complex formation using the Molecular Mechanics/Poisson-Boltzmann Surface Area (MM/PBSA) method. Our calculations reveal that α-ketoamide is more potent (ΔG[SUB]bind[/SUB]= - 9.05 kcal/mol) compared to Z31792168 (ΔG[SUB]bind[/SUB]= - 3.25 kcal/mol) against COVID-19 3CL[SUP]pro[/SUP]. The increase in ΔG[SUB]bind[/SUB] for α-ketoamide relative to Z31792168 arises due to an increase in the favorable electrostatic and van der Waals interactions between the inhibitor and 3CL[SUP]pro[/SUP]. Further, we have identified important residues controlling the 3CL[SUP]pro[/SUP]-ligand binding from per-residue based decomposition of the binding free energy. Finally, we have compared ΔG[SUB]bind[/SUB] of these two inhibitors with the anti-HIV retroviral drugs, such as lopinavir and darunavir. It is observed that α-ketoamide is more potent compared to lopinavir and darunavir. In the case of lopinavir, a decrease in van der Waals interactions is responsible for the lower binding affinity compared to α-ketoamide. On the other hand, in the case of darunavir, a decrease in the favorable intermolecular electrostatic and van der Waals interactions contributes to lower affinity compared to α-ketoamide. Our study might help in designing rational anti-coronaviral drugs targeting the SARS-CoV-2 main protease.



KEYWORDS:

Binding Free Energy; COVID-19; MM-PBSA; Molecular Dynamics; SARS-CoV-2 3CLpro


PMID:32396767DOI:10.1080/07391102.2020.1768149
 
Back
Top Bottom